Healthcare
Catheter Precision, Inc.(VTAK)
Live Price
Offline$1.05
-1.87% today
1Y Change
-79.53%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +95.0%
- EPS Growth
- -138.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Catheter Precision, Inc. (VTAK) is a Healthcare stock with listed on AMEX. The stock last traded around $1.05 and down 79.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +95.0%, EPS growth of -138.0%, a dividend yield of 0.0%. What stands out right now is revenue +95.0%, EPS -138.0%, free cash flow +11.0% with operating margin -1727.5% and ROIC -101.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VTAK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+95.0% vs +7.6% peer median
Operating Margin
Below sector median
-1727.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +95.0% and EPS is at -138.0%, with operating margin around -1727.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -1.3% | +2.6% | +36.4% |
2026 Mar 31, 2026 | +107.3% | -6.9% | -14.9% | -6.9% |
2025 Nov 13, 2025 | +93.6% | -5.4% | -24.4% | +23.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTAK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VTAK Max Drawdown
-85.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VTAK and SPY.
Company Overview
Catheter Precision, Inc.
New York Stock Exchange American
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
- Leadership
- David A. Jenkins
- IPO Date
- Sep 27, 2018
- Employees
- 22
- Street Address
- 1670 Highway 160 West
- Mailing
- Fort Mill, SC, 29708
- Region
- Fort Mill, SC, US
- Reporting Currency
- USD
- Investor Line
- 973 691 2000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.2
- Price/Book
- 144.0
Growth
- Revenue
- +95.0%
- EPS
- -138.0%
- Free Cash Flow
- +11.0%
Profitability
- Gross Margin
- 27.8%
- Operating Margin
- -1727.5%
- Net Margin
- -2086.7%
- ROE
- -239.5%
- ROIC
- -101.7%
Balance Sheet
- Debt/Equity
- 0.55
- Current Ratio
- 0.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.